Kura Oncology Inc (NASDAQ:KURA) - Share price


Stock Report

Kura Oncology Inc KURA

Last Price
$16.23

Day Change
0.23|1.44%

As of 12/08/2022
16:01:49 EDT | USD
Minimum 15 Minutes Delay.

Last Close16.00
Day Range15.90 - 16.28
Mkt Cap1.09Bil
52-Wk Range10.41 - 21.19
Yield %-
ISINUS50127T1097
Volume467,479
P/E-
P/S
P/CF-9.78

Share Price

Financials
201920202021
More ...
Income Statement
Revenue0.000.000.00
Operating Income-67.48-91.90-131.26
Net Income-63.14-89.63-130.47
Basic EPS-1.51-1.69-1.97
Avg. Diluted Shares Outstanding425366
Balance Sheet
Current Assets239.60637.29522.29
Non Current Assets2.379.9211.76
Total Assets241.97647.21534.05
Current Liabilities15.5626.0222.46
Total Liabilities---
Total Equity218.78610.91506.61
Cash Flow
Operating Cash Flow-54.76-69.83-104.55
Capital Expenditure--2.17-1.15
Free Cash Flow--72.00-105.70

In millions, except "Basic EPS". Currency is USD.

Company Profile

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Blend

Fiscal Year Ends

December

Employees

123
Key Stats
More ...
Price/Earning TTM-7.96
Price/Book2.38
Price/Sales TTM
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % TTM-∞
Net Margin % TTM-∞
ROE TTM-23.35
Debt/Equity0.01
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.